Physician profile
Jonathan B Prather
NPI 1760407167
$7,260.48
in general payments reported to CMS, 2019-2025
33 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $415 · 2021: $1,050 · 2022: $1,088 · 2023: $1,177 · 2024: $1,391 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.54 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,435.22 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $865.41 | 2019-2025 | Nucala |
| Corium, LLC | $847.03 | 2021-2025 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $801.50 | 2019-2025 | Dupixent |
| Genzyme Corporation | $797.50 | 2019-2025 | |
| Pfizer INC. | $538.30 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $224.60 | 2021-2024 | Qelbree, Qelbree |
| Incyte Corporation | $210.66 | 2021-2025 | Opzelura |
| Ironshore Pharmaceuticals INC. | $195.33 | 2019-2024 | |
| Amgen INC. | $169.26 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $157.61 | 2022-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $119.06 | 2021-2024 | |
| Tris Pharma INC | $116.86 | 2019-2023 | Dyanavel Xr |
| Hikma Pharmaceuticals USA | $102.31 | 2023-2024 | Ryaltris |
| Phadia US INC. | $83.41 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $71.38 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $71.29 | 2022-2024 | Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $54.55 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $48.93 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $47.42 | 2021 | |
| Vertical Pharmaceuticals, LLC | $35.34 | 2019 | |
| Kaleo, INC. | $33.84 | 2020-2021 | |
| Adlon Therapeutics L.P. | $28.11 | 2019-2021 | |
| Pharming Healthcare, INC. | $27.36 | 2025 | Ruconest |
| Neos Therapeutics, LP | $27.11 | 2019 | |
| Seqirus USA INC | $25.15 | 2025 | Fluad, Flucelvax |
| Aimmune Therapeutics, INC. | $24.93 | 2022 | |
| Grifols USA, LLC | $23.69 | 2024 | Xembify |
| Leo Pharma INC. | $18.33 | 2024 | Adbry |
| Optinose US, INC. | $16.37 | 2024 | |
| Alk-Abello, INC | $15.51 | 2020 | |
| Aytu Biopharma, INC. | $14.56 | 2025 | |
| Organon LLC | $12.55 | 2025 | Nexplanon, Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Prather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.